How Smart Investors Look at Albemarle (ALB).

By Harris Dyer • Wednesday, July 05 09:43 • Permanent Link

Albemarle logged a 0.3% change during today's morning session, and is now trading at a price of $230.0 per share. ALB's trading volume is 168,381 compared to the stock's average volume of 2,299,505.

Albemarle trades -12.21% away from its average analyst target price of $261.98 per share. The 25 analysts following the stock have set target prices ranging from $155.0 to $360.0, and on average have given Albemarle a rating of buy.

If you are considering an investment in ALB, you'll want to know the following:

Albemarle's current price is 68.3% above its Graham number of $136.67, which implies that at its current valuation it does not offer a margin of safety
Based on its trailing earnings per share of 32.67, Albemarle has a trailing 12 month Price to Earnings (P/E) ratio of 7.0 while the S&P 500 average is 15.97
ALB has a forward P/E ratio of 10.5 based on its forward 12 month price to earnings (EPS) of $21.96 per share
The company has a price to earnings growth (PEG) ratio of -22.57 — a number near or below 1 signifying that Albemarle is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.93 compared to its sector average of 3.78
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide.
Based in Charlotte, the company has 7,400 full time employees and a market cap of $26.99 Billion. Albemarle currently returns an annual dividend yield of 0.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.